[CLOSED] Public consultation on “the use of Intravenous immunoglobulins for Alzheimer’s disease including Mild Cognitive Impairment”
This consultation will take place between June 18th and July 15th, 2015.
Objective of public consultation
The aim of this consultation is to obtain feedback on the validity of the core HTA for its intended primary use.
A Core HTA is an extensive package of HTA information intended to serve as an information base for the production of local (e.g. national or regional) HTAs. Most information in the core HTAare presented as “result cards”, each of which contains one or few research question(s) and answer(s) to the question(s). The cards are produced and presented in a structure of nine domains (e.g. effectiveness or ethics), each providing an overview of the technology from a specific perspective.
Core HTA on Use of Intravenous immunoglobulins for Alzheimer’s disease including Mild Cognitive Impairment. The document is available at:
How to submit your comments?
Please provide any comments using the Public Consultation Survey Forms at the following link:
If you wish to draw our attention to published literature, please supply the full reference.
Please note that only comments submitted within the indicated timeframe, through the indicated online form and in accordance with the described procedure will be taken into account.
In order to be considered, the name, organisation, telephone number and e-mail address of the sender should be included in the relevant parts of the form.
The authors are unable to accept:
- Comments received after the consultation deadline
- Comments that are not completed on the online survey form
- Confidential information or other material that you would not wish to be made public
The sender should indicate if he/she submits the comments as an individual or on behalf of an organisation.
What will happen to your comments?
The responses will be processed by the WP4 Lead Partner AGENAS (Agency for Regional Healthcare, Italy). Results of the consultation, including text comments, are shared with the working groups behind the core HTA.
The contact information of all the organisations that properly submitted contributions will be made public on the EUnetHTA public website, unless the author has explicitly opposed publication of their contribution or the contributions do not address the respective consultation documents or contain complaints against institutions, personal accusations, irrelevant or offensive statements or material. The name of the author, is/her affiliation, and date of the response’s receipt will be disclosed when the contribution is made public.
All comments will be responded to by AGENAS or by members of the respective working groups in a combined document that will be posted on the EUnetHTA website after the final results of the public consultation are published.
No action will be taken upon receipt of late comments.
If responders wish to modify their response after submitting the online form, they should contact email@example.com the timeframe of the public consultation.
Final public consultation report
The final results of the public consultation will be published on EUnetHTA website.
Content of Public Consultation Survey Forms
The survey is rather extensive, but respondents can select which parts to use. Background information (page 2) about respondent and his/her organisation are (at least partially) mandatory to all respondents. Part A (page 3) contains general questions about the core HTA. We urge all participants of the public consultation to answer those questions. Part B (pages 4-12) contains nine identical pages, each focusing on one of the nine HTA domains included in the HTA Core Model. Please select any number (0-9) of these domains based on your interest. You may skip domains to which you do not want to give feedback.